HERO GRAFT
Device Facts
| Record ID | K121532 |
|---|---|
| Device Name | HERO GRAFT |
| Applicant | Hemosphere, Inc. |
| Product Code | DSY · Cardiovascular |
| Decision Date | Jun 22, 2012 |
| Decision | SESE |
| Submission Type | Special |
| Regulation | 21 CFR 870.3450 |
| Device Class | Class 2 |
| Attributes | Therapeutic |
Indications for Use
The HeRO Graft is intended for use in maintaining long-term vascular access for chronic hemodialysis patients who have exhausted peripheral venous access sites suitable for fistulas or grafts.
Device Story
HeRO Graft is a synthetic vascular access prosthesis for chronic hemodialysis; consists of three components: Arterial Graft Component (ePTFE graft with titanium connector), Venous Outflow Component (radiopaque silicone with braided reinforcing filaments), and Accessory Component Kit. During surgery, surgeon sizes Venous Outflow Component by cutting to length and sliding over connector barbs. Device provides long-term access for patients who have exhausted peripheral venous sites. Implanted by surgeons; provides durable outflow to maintain hemodialysis access; benefits patients by reducing reliance on catheters and improving dialysis clearance.
Clinical Evidence
No clinical data was required to support this modification. Substantial equivalence is supported by design verification testing.
Technological Characteristics
Synthetic vascular graft prosthesis. Materials: ePTFE (arterial component), radiopaque silicone with braided reinforcing filaments (venous outflow component), titanium (connector). Form factor: multi-component assembly. Non-active device.
Indications for Use
Indicated for end stage renal disease patients on hemodialysis who have exhausted all other access options, including those who are catheter-dependent or approaching catheter-dependency, are not candidates for upper extremity fistulas/grafts due to poor venous outflow, are failing existing fistulas/grafts, have poor remaining venous access sites, have compromised central venous systems or central venous stenosis, or are receiving inadequate dialysis clearance via catheters.
Regulatory Classification
Identification
A vascular graft prosthesis is an implanted device intended to repair, replace, or bypass sections of native or artificial vessels, excluding coronary or cerebral vasculature, and to provide vascular access. It is commonly constructed of materials such as polyethylene terephthalate and polytetrafluoroethylene, and it may be coated with a biological coating, such as albumin or collagen, or a synthetic coating, such as silicone. The graft structure itself is not made of materials of animal origin, including human umbilical cords.
Special Controls
*Classification.* Class II (special controls). The special control for this device is the FDA guidance document entitled “Guidance Document for Vascular Prostheses 510(k) Submissions.”
Predicate Devices
Submission Summary (Full Text)
{0}------------------------------------------------
K121532
# 510(k) Summary · (per 21 CFR 807.87(h))
JUN 2 2 2012
| Common/Usual Name: | Vascular Graft Prosthesis |
|----------------------|------------------------------------------------------------------------------------|
| Product Trade Name: | HeRO® Graft |
| Classification Name: | 21 CFR 870.3450; Vascular graft prosthesis; Class<br>II; DSY, LJS, MSD, Cardiology |
| Predicate Device: | K071778, K091491 HeRO™ Vascular Access Device<br>K120006 HeRO® Graft |
| Manufacturer: | Hemosphere, Inc.<br>6545 City West Parkway<br>Eden Prairie, MN 55344 |
Contact:
Laurie E. Lynch, Ph.D. Director QA/RA/R&D
Date Prepared:
May 11, 2012
## Device Description:
The HeRO Graft is a non-autogenous (i.e., synthetic) vascular graft prosthesis composed of three components: Arterial Graft Component, Venous Outflow Component and Accessory Component Kit. The Venous Outflow Component is made of radiopaque silicone and contains reinforcing braided filaments that impart kink and crush resistance. During surgery, the Venous Outflow Component is sized to fit the patient by cutting it to the proper length and sliding it over the barbs of the connector on the Arterial Graft Component. The Arterial Graft Component is a conventional ePTFE hemodialysis graft that has been attached to a titanium connector. The Accessory Component Kit (a convenience kit) contains instruments that assist in the implantation of the HeRO Graft.
#### Intended Use:
The HeRO Graft is intended for use in maintaining long-term vascular access for chronic hemodialysis patients who have exhausted peripheral venous access sites suitable for fistulas or grafts.
{1}------------------------------------------------
## Indications for Use:
The HeRO Graft is indicated for end stage renal disease patients on hemodialysis who have exhausted all other access options. These catheter-dependent patients are readily identified using the KDOQI guidelines' as patients who:
- . Have become catheter-dependent or who are approaching catheter-dependency (i.e.. have exhausted all other access options, such as arteriovenous fistulas and grafts).
- Are not candidates for upper extremity fistulas or grafts due to poor venous outflow as . determined by a history of previous access failures or venography.
- Are failing fistulas or grafts due to poor venous outflow as determined by access failure . or venography (e.g. fistula/graft salvage).
- Have poor remaining venous access sites for creation of a fistula or graft as determined . by ultrasound or venography.
- Have a compromised central venous system or central venous stenosis (CVS) as . determined by history or previous access failures, symptomatic CVS (i.e., via arm, neck, or face swelling) or venography.
- . Are receiving inadequate dialysis clearance (i.e., low Kt/V) via catheters. KDOQI guidelines recommend a minimum Kt/V of 1.4.2
### Substantial Equivalence Comparison:
The predicate device is the GRAFTcath, Inc. HeRO Vascular Access Device, K071778, K091491 and K120006. The company name has been changed from GRAFTcath, Inc. to Hemosphere, Inc. and the product name has been changed from HeRO Vascular Access Device to HeRO Graft.
Results of design verification testing demonstrate that the device system as modified is as safe as the predicate device. The risk assessment results, together with the results of design verification testing presented in this submission, confirm that the HeRO Graft, as modified, raises no new questions of safety or effectiveness compared to the predicate device. The HeRO Graft has been shown to be substantially equivalent to the legally marketed device for the purpose of 510(k) clearance.
## Summary of Non-Clinical & Clinical Performance Data:
No changes were made to the previously cleared packaging verification and sterilization validation. Additional clinical performance data was not required to support the modification of the device.
<sup>1</sup> Vascular Access Work Group. National Kidney Foundation KDOQI clinical practice quidelines for vascular access. Guideline 1: patient preparation for permanent hemodialysis access. Am J Kidney Dis 2006,48(1Suppl1):S188-91. 4 Hemodialysis Adequacy 2006 Work Group. National Kidney Foundation KDOQI clinical practice quidelines for hemodialysis adequacy, update 2006. Am J Kidney Dis 2006:48(Suppl 1):S2-S90.
{2}------------------------------------------------
Image /page/2/Picture/1 description: The image shows the logo for the Department of Health & Human Services USA. The logo features a stylized eagle with three swooping lines representing its wings. The words "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" are arranged in a circular fashion around the eagle.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Room -WO66-G609 Silver Spring, MD 20993-0002
Hemosphere, Inc. c/o Laurie E. Lynch, Ph.D. Director, QA/RA/R&D 6545 City West Parkway Eden Prairie, MN 55344
JUN 2 2 2012
Re: K121532
Trade/Device Name: HeRO® Graft Regulation Number: 21 CFR 870.3450 Regulation Name: Vascular Graft Prosthesis Regulatory Class: Class II Product Code: DSY Dated: May 23, 2012 Received: May 24, 2012
Dear Dr. Lynch:
We have reviewed your Section 510(k) premarket notification of intent to market the indication We have reviewed your Section 310(k) prematic is substantially equivalent (for the indications
referenced above and have determined the device is substanterled in interstate referenced above and have determined the devices marketed in interstate
for use stated in the enclosure) to legally marketed president Device, mendments. for use stated in the enclosure) to regary market of the Medical Device Amendments, or to
commerce prior to May 28, 1976, the enactment of the Medical Device American Food. D commerce prior to May 28, 1976, the elacultien and of the Federal Food. Drug, devices that have been reclassified in accordance was assessmoval application (PMA).
and Cosmetic Act (Act) that do not require approval assuresisions of the Act. The and Cosmetic Act (Act) that do not require approvate of the general controls provisions of the Act. The Act. The You may, therefore, market the device, subject of the general or annual registration, listing of
general controls provisions of the Act include requirements for annual regist general controls provisions of the Accurations against misbranding and devices, good manufacturing practice, rademig, and promonone related to contract liability.
adulteration. Please note: CDRH doesh or evaluate information related to adulteration. Please note: CDKFI does not evaluate international
warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it
and be If your device is classified (see and on into cince of (spinss affecting your device can be
may be subject to additional controls. Existing major regulations affecting your may be subject to additional controls. Exismig major regarators and man and more of the may
found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In additio found in the Code of Federal Regulations, This Beyone in the Federal Register.
publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean
ts of the Active that the start of the complies with other requirements of the Please be advised that FDA's issuance of a substance of the requirements of the Act
that FDA has made a determination that your device complies with of the Act that FDA has made a determination una your areas by other Federal agencies. You must
or any Federal statutes and regulations administered by other Federal on and listin or any Federal statutes and regulations and limited to: registration and listing (21
comply with all the Act's requirements, including, but not limited to registration of med comply with all the Act's requirements, micruding, out not minted on region
CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical
{3}------------------------------------------------
Page 2 - Laurie E. Lynch, Ph.D.
comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH0ffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm.
Sincerely youns.
Sincerely yours,
Bram D. Zuckerman, M.D. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{4}------------------------------------------------
# INDICATIONS FOR USE STATEMENT
Current 510(k) Number: K121532
Device Name:
HeRO® Graft
#### Indications for Use:
The HeRO® Graft is indicated for end stage renal disease patients on hemodialysis who have exhausted all other access options. These catheter-dependent patients are readily identified using the KDOQI guidelines1 as patients who:
- Have become catheter-dependent or who are approaching catheter-dependency (i.e., have exhausted all other access options, such as arteriovenous fistulas and grafts).
- Are not candidates for upper extremity fistulas or grafts due to poor venous outflow as determined by a history of previous access failures or venography.
- Are failing fistulas or grafts due to poor venous outflow as determined by access failure or venography (e.g. fistula/graft salvage).
- Have poor remaining venous access sites for creation of a fistula or graft as determined . by ultrasound or venography.
- Have a compromised central venous system or central venous stenosis (CVS) as . determined by history or previous access failures, symptomatic CVS (i.e., via arm, neck, or face swelling) or venography.
- Are receiving inadequate dialysis clearance (i.e., low Kt/V) via catheters. KDOQI . guidelines recommend a minimum Kt/V of 1.4.2
Vascular Access Work Group. National Kidney Foundation KDOQ! clinical practice guidelines for vascular access. Guideline 1: patient preparation for permanent hemodialysis access. Am J Kidney Dis 2006;48(1Suppl1):S188-91. 2 Hemodialysis Adequacy 2006 Work Group. National Kidney Foundation KDOQI clinical practice guidelines for hemodialysis adequacy, update 2006. Am J Kidney Dis 2006;48(Suppl 1):S2-S90.
Prescription Use (Part 21 CFR 801 Subpart D) AND/OR
Over-The-Counter Use (21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
(Divi
Division cardioprcular Devices
510(k) Number K121532
